ContraVir Pharmaceuticals,Inc. (NASDAQ:CTRV) Files An 8-K Other EventsItem 8.01 Other Events
On October19, 2017, ContraVir Pharmaceuticals,Inc. issued a press release announcing it has dosed its first patient in the IND opening, Phase 1 study of tenofovir exalidex (TXL™) in renally-impaired patients.
The press release is attached as Exhibit99.1 to this report on Form8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits
|
99.1 |
ContraVir Pharmaceuticals,Inc. Press Release dated October19, 2017 |
ContraVir Pharmaceuticals, Inc. ExhibitEX-99.1 2 a17-24220_1ex99d1.htm EX-99.1 Exhibit 99.1 ContraVir Pharmaceuticals Initiated Dosing of Renally-Impaired Patients in First U.S. Trial with TXL™ EDISON,…To view the full exhibit click here
About ContraVir Pharmaceuticals,Inc. (NASDAQ:CTRV)
ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100. The Company’s CMX157 is a lipid acyclic nucleoside phosphonate that delivers intracellular concentrations of the active antiviral agent tenofovir diphosphate. The Company has completed a Phase I clinical trial of CMX157. The Company’s CRV431 drug candidate is designed to target cyclophilins, which are a class of proteins. CRV431 inhibits the role of host cyclophilins and interferes in the propagation of the viruses. The Company’s FV-100 is an orally available, small molecule, nucleoside analogue pro-drug of CF-1743, which is used for the treatment of herpes zoster. It has developed FV-100 for the treatment of shingles.
